Date: 2026-03-01Category: Press ReleaseState: Union GovernmentCountry: India
Dr Jitendra Singh inaugurates Central Facility for Recombinant Cells and Sensors at BRIC-RGCB Thiruvananthapuram, Keralam; developed at a cost of approximately Rs 60 cr, the new facility promises to boost Drug Discovery and Medical, Agri Genomics
**Executive Summary**
Union Minister Dr. Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-RGCB in Thiruvananthapuram, Kerala, developed at a cost of approximately Rs 60 crore. The facility aims to boost drug discovery, medical advancements, and agri-genomics. The Minister also announced the establishment of a new GMP facility at BRIC-RGCB, with an investment of Rs. 80 crores.
**Key Points / Main Content**
* **New Facility Inauguration:**
* Inauguration of "Central Facility for Recombinant Cells and Sensors" at BRIC-RGCB (Rajiv Gandhi Centre for Biotechnology).
* Cost: Approximately Rs 60 crore.
* Purpose: To accelerate target-specific drug discovery and screening, benefiting academia, industry, and healthcare innovators.
* **Bioeconomy Growth and Policy:**
* India's bioeconomy has expanded from around $10 billion to $166 billion in the past decade.
* The goal is to reach $300 billion in the coming years.
* The number of biotech startups has grown from 50–70 in 2014 to over 11,000 today.
* India is one of the few countries with a dedicated BioE3 policy focused on economy, environment, and employment.
* **GMP Facility Establishment:**
* A new dedicated GMP facility will be established at BRIC-RGCB.
* Purpose: To support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy.
* Operation: The facility will function as a bridge between laboratory research and industrial-scale production on a “pay-and-use” basis.
* Investment: Rs. 80 crores by DBT; the project will be implemented in two phases.
* **Healthcare and Research Focus:**
* Focus on addressing the rising burden of non-communicable diseases like diabetes, fatty liver disease, and cancer.
* Emphasis on research in cancer biology, including colon, oral, breast, and cervical cancers.
* Promotion of preventive healthcare alongside advanced research, referencing HPV vaccination.
* Increased investment in the country's biotechnology sector.
**Impact Analysis**
**BRIC-RGCB and Research Institutions**
* **Impact:** Receives new facilities (Central Facility and GMP Facility) to enhance research capabilities and production.
* **Action Required:** Utilize the new facilities to accelerate drug discovery, develop cell-based therapies, and foster collaboration with clinical centers.
**Academia, Industry, and Healthcare Innovators**
* **Impact:** Benefit from the Central Facility's advanced screening systems and access to engineered recombinant cells, accelerating drug discovery. GMP facility will enable access to pre-commercial production of biologics and cell-based therapies.
* **Action Required:** Engage with BRIC-RGCB to utilize the facilities for research, development, and commercialization purposes.
**Biotech Start-ups**
* **Impact:** Benefit from government support for innovation and entrepreneurship in the biotechnology sector.
* **Action Required:** Take advantage of the expanding ecosystem and government support to foster innovation and growth in the biotech industry.
**Scientific Community (Scientists, Students, Researchers)**
* **Impact:** Receive backing and support to translate research into real-world applications.
* **Action Required:** Leverage the policy support, funding mechanisms, and collaborative opportunities to advance research and innovation.
**Coastal States (e.g., Kerala)**
* **Impact:** Encouraged to align biotechnology capabilities with national missions, including marine biodiversity and fisheries-linked innovation.
* **Action Required:** Focus on developing and integrating biotechnology capabilities in coastal areas to support national missions and sustainable development.
Key Entities Referenced
BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB): Location of the Central Facility for Recombinant Cells and Sensors and new GMP facility.
BioE3 Policy: A biotechnology policy focused on economy, environment, and employment.
Department of Biotechnology: Department that invested in creating the Central Facility for Recombinant Cells and Sensors.
Thiruvananthapuram, Kerala: Location of the BRIC-RGCB and the Central Facility.
Dr Jitendra Singh: Union Minister who inaugurated the Central Facility.
Ministry of Science & Technology
Dr Jitendra Singh inaugurates Central Facility for
Recombinant Cells and Sensors at BRIC-RGCB
Thiruvananthapuram, Keralam; developed at a
cost of approximately Rs 60 cr, the new facility
promises to boost Drug Discovery and Medical,
Agri Genomics
From around 50 to over 11,000 Biotech Start-Ups in 11 years,
Signal India’s Shift Towards a Bio-Driven Economy, says
Union Minister Dr Jitendra Singh
BioE3 Policy to Power India’s $300 Billion Biomanufacturing
Future; Bioeconomy Grows 16-Fold in a Decade: Dr Jitendra
Singh
New GMP Facility at BRIC-RGCB to Boost CAR-T & Cell-
Based Therapies; Science to Drive Economic Growth and
Public Health Outcomes: Dr Jitendra Singh
Posted On: 01 MAR 2026 3:14PM by PIB Delhi
Union Minister of State (Independent Charge) for Science & Technology, Earth Sciences; MoS PMO,
Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh today inaugurated
the new state-of-the-art "Central Facility for Recombinant Cells and Sensors" at BRIC-Rajiv Gandhi
Centre for Biotechnology. The new Recombinant Cell facility promises to boost drug discovery as well as
medical and Agri genomics.
The Minister also announced the foundation of a dedicated GMP facility, and released the book “Quantum
Physics: One Hundred Magical Years” authored by Prof. V.P.N. Nampoori.
Speaking on the occasion, Dr Jitendra Singh said that India is preparing for a bio-driven economy where
biotechnology will shape the future of manufacturing, healthcare, and sustainable growth.
The Minister said that in the last decade, under the leadership of Prime Minister Narendra Modi,
biotechnology has received unprecedented policy support, enabling India to emerge as a global
biotechnology hub. Referring to the recently launched BioE3 Policy, he said, India is among the few
countries to bring out a dedicated biotechnology policy focused on economy, environment, and
employment, anticipating the global shift towards biomanufacturing and bio-based industries.The Union Minister was addressing scientists, students, and industry representatives during his visit to
BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) at its Akkulam campus in
Thiruvananthapuram, Keralam, on National Science Day. The event was attended by Dr. Rajesh S.
Gokhale, Secretary, Department of Biotechnology; Dr. Santosh, Director, BRIC-RGCB; senior scientists,
faculty members, start-up incubatees and students.
Referring to India’s biotechnology growth, Dr Jitendra Singh said, the country’s bioeconomy has
expanded nearly sixteen times over the past decade, growing from around 10 billion US dollars to nearly
166 billion US dollars, with a target of reaching 300 billion US dollars in the coming years. He said the
number of biotechnology start-ups has risen from about 50–70 in 2014 to over 11,000 today, reflecting the
expanding innovation ecosystem supported by policy reforms and dedicated funding mechanisms,
including recent initiatives for deep-tech start-ups.
About the BRIC-RGCB’s new Central Facility for Recombinant Cells and Sensors, the Minister said the
facility represents years of sustained research support and will significantly accelerate target-specific drug
discovery and screening. The facility houses a large panel of engineered recombinant cells and advanced
screening systems, developed through long-term government-supported programmes, and will serve
academia, industry, and healthcare innovators across the country. The Department of Biotechnology has
invested approximately Rs. 60 crores in creating this facility.
Dr Jitendra Singh also spoke about the rising burden of non-communicable diseases, including diabetes,
fatty liver disease,and cancer. He said India is witnessing a steady rise in cancer incidence, with
projections indicating a significant increase by 2030. In this context, he appreciated the institute’s research
in cancer biology, including work on colon, oral, breast and cervical cancers. Referring to HPV
vaccination, he recalled that India’s scientific institutions have contributed to global evidence supporting
simplified vaccination schedules, and said preventive healthcare must go hand in hand with advanced
research.
Announcing the establishment of a dedicated GMP facility at BRIC-RGCB, the Minister said the
upcoming facility will support pre-commercial production of biologics and cell-based therapies, including
CAR-T therapy, in collaboration with clinical centres in Keralam. The facility will function as a bridge
between laboratory research and industrial-scale production and will be available to biotech industries on
a “pay-and-use” basis. The project will be implemented in two phases with a total investment of Rs. 80
crores by DBT.
The Minister also called for deeper collaboration among research institutions, private industry and
emerging sectors such as nuclear medicine and deep-ocean research. He said recent policy measures have
opened new avenues for private participation in advanced research domains and encouraged institutions in
coastal states like Kerala to align biotechnology capabilities with national missions, including marine
biodiversity and fisheries-linked innovation.
Dr Jitendra Singh said India’s scientific community today benefits from strong policy backing and
decisive support at the highest level, enabling faster translation of research into real-world applications.
He encouraged young researchers to take advantage of the expanding ecosystem and assured continued
government support for innovation, entrepreneurship, and interdisciplinary collaboration.PHOTO : Union Minister Dr Jitendra Singh inaugurating new state-of-the-art facility at BRIC-Rajiv
Gandhi Centre for Biotechnology at Thiruvananthapuram, Keralam.*****
NKR/AK/AV
(Release ID: 2234170) Visitor Counter : 254
Read this release in: Urdu , ही , Tamil